JNK pathway suppression drives resistance to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer
C. Elizabeth Caldon(Garvan Institute of Medical Research), Henrik J. Ditzel(University of Southern Denmark)
Cited by 0
Related Papers
Cell cycle control in breast cancer cells
|Journal of Cellular Biochemistry|2005|234
Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
|Nature Communications|2021|82
Functional Heterogeneity within the CD44 High Human Breast Cancer Stem Cell-Like Compartment Reveals a Gene Signature Predictive of Distant Metastasis
|Molecular Medicine|2012|79
Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
|npj Precision Oncology|2022|72
Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells
|npj Precision Oncology|2021|46